Inhibitex has signed a licensing agreement worth up to $4 million with 3M for the development of various diagnostic products.

The products will be based on Inhibitex platform technology. Inhibitex will receive license fees, milestone payments, financial support for additional research, and royalty payments.

Inhibitex develops and commercializes antibody-based products for the prevention and treatment of serious infections.